AD NUMBER

ADB220575

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 96. Other requests shall be referred to Commander, Attn: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

AUTHORITY

USAMRMC ltr dtd 26 Jan 2000

AD_____

GRANT NUMBER DAMD17-94-J-4394

TITLE: Gene Therapy of Breast Cancer: Studies of Selection Promoter/Enhancer-Modified Vectors to Deliver Suicide Genes

PRINCIPAL INVESTIGATOR: Donald W. Kufe, M.D.

CONTRACTING ORGANIZATION: Dana-Farber Cancer Institute
Boston, MA 02115-6084

REPORT DATE: September 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	September 1996	Annual (1 Sep 95 - 31 Aug 96)

4. TITLE AND SUBTITLE Gene Therapy of Breast Cancer: Studies of Selection Promoter/Enhancer-Modified Vectors to Deliver Suicide Genes

5. FUNDING NUMBERS
DAMD17-94-J-4394

6. AUTHOR(S)
Donald W. Kufe, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Dana-Farber Cancer Institute
Boston, MA 02115-6084

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick
Frederick, Maryland 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Distribution authorized to U.S. Government agencies only; Proprietary Information, Sep 96. Other requests for this document shall be referred to Comander, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200 words)*
Tumor contamination of bone marrow (BM) and peripheral blood (PB) may affect the outcome of patients receiving high dose chemotherapy with autologous transplantation of hematopoietic stem cell products. We demonstrate that replication defective adenoviral vectors containing DF3/MUC1 carcinoma-selective promoter can be used to selectively transduce contaminating carcinoma cells. Adenoviral-mediated reporter gene expression in breast cancer cells was 5-6 orders of magnitude higher than that found in BM, PB and $CD34^+$ cells and can detect one breast cancer cell in 5 x 10^5 BM or PB cells with a vector containing the DF3/MUC1 promoter. We also show that transduction of the HSV-tk gene for selective killing by ganciclovir (GCV) can be exploited for purging cancer cells. The selective expression of TK followed by GCV treatment resulted in the elimination of 6-logs of contaminating cancer cells. There was little effect on CFU-GM and BFU-E or LTCICs. These results indicate that adenoviral vectors with a tumor-selective promoter provide a highly efficient and effective approach for the detection and purging of carcinoma cells in hematopoietic stem cell preparations.

14. SUBJECT TERMS	15. NUMBER OF PAGES
Breast Cancer	39
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Limited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

DWK Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

DWK In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

DWK In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

DWK In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

DWK In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

D.W. Kr 9/24/96

PI - Signature Date

Gene Therapy of Breast Cancer: Studies of selection Promoter/Enhancer-modified Vectors to Deliver Suicide Genes

Contents

INTRODUCTION

High dose chemotherapy followed by autologous transplantation of bone marrow (BM) or peripheral blood (PB) as sources of hematopoietic stem cells is being used as a treatment option for patients with breast cancer[1-4]. While this approach results in a proportion of patients with prolonged disease-free survival, most patients eventually relapse. One potential explanation for relapse is reinfusion of tumor cells that contaminate the hematopoietic cell preparations[5-7]. Immunocytochemistry[5,8], flow cytometry[8,9] and PCR analysis[10,11] have been used to detect contaminating breast cancer cells in BM and PB preparations. Although the significance of breast cancer cell contamination to relapse remains unclear, tumor-free hematopoietic stem cell products for autologous transplantation are nonetheless desirable. In this context, various approaches using monoclonal antibodies (MAbs) or cytotoxic drugs have been developed for purging of carcinoma cells from BM or PB collections[12-17]. These approaches have resulted in the elimination of 2-5 logs of clonogenic breast cancer cells and varying degrees of toxicity to hematopoietic progenitor and stem cells.

Gene therapy is a potentially novel approach for the purging of carcinoma cells from hematopoietic stem cell preparations. However, efficacy of purging cancer cells will require gene delivery systems which possess a high gene transduction efficiency and target cell specificity. Human adenoviruses are non-enveloped double-stranded DNA viruses which when deleted at the E1 region are replication defective[18]. Adenovirus-mediated gene transfer is

a highly efficient means of delivering genetic material into a wide spectrum of cells in vitro and in animals. However, in the setting of bone marrow purging, one goal is the selective transduction of exogenous genes into contaminating cancer cells. A potential strategy to achieve such selectivity would be to use a tumor cell specific/selective promoter to direct the expression of a therapeutic gene in the desired target cell. In this context, recent studies have demonstrated that the promoter of the DF3/MUC1 gene can be used to confer selective expression of heterologous genes in breast cancer cells[19,20]. DF3/MUC1 antigen is a member of a family of high molecular weight glycoproteins which are aberrantly overexpressed in breast and other carcinomas[21-23]. Adenoviral vectors containing the β-galactosidase or the HSV-tk gene under control of the DF3 promoter have thus been developed to confer efficient and selective expression of these genes in cancer cells[20].

In the present work, we demonstrate that adenoviral vectors containing the DF3/MUC1 promoter can be used for detection of carcinoma cells in preparations of hematopoietic stem cell sources. The results also demonstrate that selective expression of therapeutic genes in contaminating cancer cells is an efficient approach for purging of hematopoietic stem and progenitor cells.

BODY

Experimental Methods

Cell lines. The MCF-7, ZR-75-1, BT-20 and SKBR3 breast carcinoma, the A549 lung carcinoma, DU145 prostate carcinoma, SKOV3 ovarian carcinoma and T98G human glioblastoma cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD). Cells were grown as monolayers in recommended culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.

Human hematopoietic cells. Human PB mononuclear cells were isolated by Ficoll-Paque (Pharmacia, Piscataway, NJ) density gradient centrifugation (d=1.077, 400 x g) from leukocyte-enriched leukopaks of healthy donors. Cells were suspended in RPMI 1640 medium containing 10% heat-inactivated FBS, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Bone marrow was obtained from filters used to prepare harvested marrow from normal donors and the mononuclear cells were isolated by Ficoll-Paque density gradient centrifugation. Bone marrow stromal cells were isolated by adherence[24].

$CD34^+$ cells were isolated using the Ceprate LC cell separation system (CellPro Inc., Bothell, WA). In brief, BM cells were incubated with a biotinylated mouse anti-CD34+ MAb, washed and then passed through an avidin column. Nonadsorbed cells were removed by washing, and adsorbed cells were eluted from the column. The enriched cells (80-90% CD34+) were maintained in

Iscove's MEM containing 12.5% FBS, 12.5% horse serum and 1 μM hydrocortisone.

Antibody reaction and fluorescence-activated cell sorting (FACS) analysis. Monoclonal antibodies (MAbs) used were specifically reactive with the cell surface antigens: CD3 (T3, Coulter, Miami, FL), CD13 (L138, Becton Dickinson), CD19 (B4, Coulter), CD34 (Becton Dickinson, San Jose, CA), CD51 (integrin αv, clone 1980, Chemicon Inc., Temecula, CA), integrin αvβ3 (LM609, kindly provided by Dr. David Cheresh, Scripps Research Institute, CA) and integrin αvβ5[25] (Clone B5-IA9, generously provided by Dr. Martin E. Hemler, Dana-Farber Cancer Institute). Cells were incubated with antibody for 30 min on ice. If the antibody was not directly conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE), a secondary antibody conjugated with FITC or PE (SIGMA, St. Louis, MO) was used for indirect fluorescence labeling. Cells were then washed and evaluated by flow cytometric analysis.

Recombinant adenoviruses. Ad.CMV-βgal, Ad.CMV-tk[20], and Ad.CMV-Luc (kindly provided by Dr. Robert Gerard, University of Texas)[26] are replication-deficient recombinant adenoviruses in which the luciferase, β-galactosidase, and HSV-tk genes, respectively, are under control of the cytomegalovirus (CMV) immediate-early promoter and enhancer. Ad.DF3-βgal and Ad.DF3-tk are recombinant adenoviruses in which the specified genes are under control of the DF3/MUC1 tumor-selective promoter[20,27]. Adenoviral vectors were produced by homologous recombination in the human embryonic kidney cell line 293 as described[28]. Large

scale production of recombinant adenovirus was accomplished by growth in 293 cells and purification by double cesium gradient ultracentrifugation as described[28]. Titers of purified adenovirus were determined by spectrophotometry and by plaque assays.

Adenovirus infection. Cells suspended at 0.5 to 2 x 10^6/ml culture medium were infected with adenoviruses at a multiplicity of infection (MOI) of 1 to 1000 for 2 h, washed and then resuspended in fresh media. Cells were evaluated for the expression of the transgene at 24 to 48 h post infection.

Assay for luciferase activity. Luciferase activity was measured with D-luciferin (Analytical Luminescence Laboratory, San Diegi, CA) using a luminometer. Activity is presented as relative luminescent units (RLU) in an indicated number of cells.

Assays for β-galactosidase. (i) Chemiluminescence assay. Quantitation of enzyme activity was determined by a chemiluminescence assay using Galacto-Light system (Tropix, Inc., Bedford, MA) that detects 2 fg to 20 ng of β-galactosidase[29]. Activity is presented as relative luminescent units (RLU) in an indicated number of cells. ii) Histochemical staining. Cells were fixed with 0.5% glutaraldehyde in phosphate-buffered saline (PBS) containing 1 mM $MgCl_2$ for 10 min, rinsed with PBS, and then incubated with X-Gal (1 mg/ml), 5 mM $K_3Fe(CN)_6$, 5 mM $K_4Fe(CN)_6$, 1 mM $MgCl_2$ in PBS for 4 h. (iii) FACS-GAL assay[30]. Briefly, 0.5-1 x 10^6 cells were suspended in 50 µl of serum-free culture medium at 37°C. An equal volume of 2 mM fluorescein di-β-D-galactopyranoside (FDG; Molecular Probes, Eugene, OR) was added to each aliquot of cells. The cells and FDG were mixed rapidly and incubated for 1

min at 37°C. Thereafter, cells were washed once with 4 ml ice-cold PBS and maintained in ice-cold PBS until analysis.

Tumor cell clonogenic assay. At 24 h after adenovirus infection, ganciclovir (GCV) was added to cells and incubated for 24 h. Serial dilutions of cells were plated on 30-mm culture dishes. Cells were incubated for 2 wks, and colonies (>50 cells) were stained with crystal violet and counted. Results are expressed as the surviving cell fraction ± SEM for the treated groups compared to controls.

Hematopoietic progenitor cell assays. Erythroid burst-forming units (BFU-E) and granulocyte-monocyte colony-forming units (CFU-GM) were assayed in a methylcellulose culture system (Stem Cell Technologies, Vancouver, British Columbia, Canada) containing recombinant human stem cell factor (50 ng/ml), GM-CSF (10 ng/ml), IL-3 (10 ng/ml), and erythropoietin (EPO) (3 U/ml). The numbers of colonies were counted after two weeks. For more primitive progenitor cells, the number of long-term culture-initiating cells (LTC-ICs) were determined by culturing serial dilutions of $CD34^+$ cells on irradiated bone marrow stromal cells in 96-well plates for 5 weeks. The number of wells that contained colonies was then assessed by growth in methylcellulose culture (Stem Cell Technologies)[24]. The frequency of LTC-ICs was calculated by plotting the input cell number against the proportion of negative wells as described[24,31].

Polymerase chain reaction (PCR) analysis. CD34+ cells, CFU-GM and BFU-E picked from methylcellulose culture were digested at 56°C for 1-2 h with proteinase K (2 mg/ml) in cell lysis buffer

containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM $MgCl_2$, 0.1 mg/ml gelatin (Sigma), 0.45% NP40, and 0.45% Tween 20, as described[32]. Samples were then heated at 95°C for 5 min. DNA was amplified using the GeneAmp PCR reagent kit (Perkin Elmer/Cetus, Norwalk, CT). The β-actin gene was used as an internal control and amplified using the primers 5'TCACCCACACTGTGCCCAT3' and 5'GCATTTGCGGTGGACGATG3'. The adenovirus E1A gene was amplified using primers 5'ATTACCGAAGAAATGGCCGC3' and 5'CCCATTTAACACGCCATG3'. The adenovirus E2B gene was amplified using primers 5'TCGTTTCTCAGCAGCTGTTG3' and 5'CATCTGAACTCAAAGCGTGG3' as described [33].

Statistical analysis. Results are presented as means ± SEM. Data comparisons were made by ANOVA. Pairwise comparisons were made using Fisher's PLSD[34] with STATVIEW 4.0 software (Abacus Concepts, Inc., Berkley, CA).

RESULTS

The efficiency of adenovirus-mediated reporter gene expression was first evaluated in hematopoietic cell preparations using Ad.CMV-Luc and Ad.CMV-βgal. Luciferase and β-galactosidase activities were low but detectable in unfractionated PB and BM mononuclear cells at MOIs of 10 and 100 (Fig. 1A). By contrast, there was little if any detectable reporter gene expression in these cells when using Ad.DF3-βgal (Fig. 1A). Similar studies in MCF-7 breast cancer cells demonstrated a marked increase in efficiency (5-6 orders of magnitude) of Ad.CMV-Luc and Ad.CMV-βgal-mediated reporter gene expression (Fig. 1B). Moreover, as previously demonstrated[20], β-galactosidase expression was readily detectable in MCF-7 cells transduced with Ad.DF3-βgal (Fig. 1B). These findings indicated that MCF-7 cells are transduced more efficiently than hematopoietic cells by adenoviral vectors and that the tumor-selective DF3/MUC1 promoter can confer even greater selectivity of transgene expression. Two-color FACS-analysis further indicated that monocytes and macrophages ($CD14^+$ cells) are the major cell types in PB that express β-galactosidase when infected with Ad.CMV-βgal and not with Ad.DF3-βgal, while T ($CD3^+$) and B ($CD19^+$) cells express little if any transgene with either vector (data not shown).

To determine if adenovirus mediates transgene expression in $CD34^+$ hematopoietic stem and progenitor cells, we performed two-color FACs analysis of enriched $CD34^+$ cells infected with Ad.CMV-βgal. At a MOI of 100, less than 4% of $CD34^+$ cells expressed the transgene, while approximately 11% of the $CD34^+$ cells were βgal

positive at a MOI of 1000 (Fig. 2A). These findings indicated that transduction of $CD34^+$ cells is inefficient compared to that for MCF-7 cells. A sensitive chemiluminescent assay showed that there was little β-galactosidase expression when enriched $CD34^+$ cells were transduced with Ad.CMV-βgal (~2,000 RLU/10^4 cells at a MOI = 10) and no β-galactosidase expression with Ad.DF3-βgal (Fig. 2B). By contrast to the $CD34^+$ cells, bone marrow stromal cells were transduced efficiently by Ad.CMV-βgal (10^6 RLU/10^4 cells at a MOI = 10) (Fig. 2B). Moreover, the stromal cells exhibited little β-galactosidase expression following transduction with Ad.DF3-βgal (Fig. 2B). To substantiate the relatively low infectability of CD34+ cells by adenovirus, we used PCR to determine the relative copy number of virus per cell after infection. Purified bright $CD34^+$ cells infected with adenovirus were obtained by fluorescence sorting and DNA was extracted for PCR analysis of adenoviral E2B sequences. There was no detectable adenovirus in 10^3 $CD34^+$ cells infected at a MOI of 10, while the E2B signal was readily apparent from 10^3 transduced MCF-7 cells (Fig. 2C). A low level signal was obtained when assaying 10^4 infected $CD34^+$ cells (Fig. 2C). By comparison with an adenovirus standard, we estimate that there are approximately 10 copies of virus per MCF-7 cell and less than 0.01 copy per $CD34^+$ cell when cells were infected with adenovirus at a MOI of 10.

Adenovirus infection is a two step process involving the initial attachment of adenoviral fiber protein to a relatively ubiquitously expressed, but yet unidentified, receptor and then internalization through interaction of the adenoviral penton base

with αv integrins, particularly αvβ3 and αvβ5 heterodimers[35,36]. FACS analysis indicated that $CD34^+$ cells had no detectable αv subunits, αvβ3 or αvβ5 (Table I). By contrast, αv subunits were strongly expressed on breast cancer, lung cancer, prostate cancer and glioblastoma cells (Table I). The tumor cells expressed αvβ5 at high levels and αvβ3 to a lesser extent (Table I). These results indicated that the low level of adenoviral-mediated transduction in $CD34^+$, as compared to carcinoma, cells is attributable at least in part to the absence of integrins that contribute to adenoviral internalization.

The finding that adenovirus preferentially transduces carcinoma, as compared to hematopoietic, cells suggested that adenoviral-mediated reporter gene expression could be used to detect contaminating cancer cells in PB and BM. To address this issue, MCF-7 cells were premixed with PB cells at ratios of $1:10^2$ to $2:10^6$. Reporter activity of Ad.CMV-Luc- and Ad.CMV-βgal-infected cell mixtures reflected the number of contaminating MCF-7 cells (Table II). The level of luciferase activity mediated by Ad.CMV-Luc infection was significantly increased at a ratio of ten MCF-7 cell/5 x 10^5 PB mononuclear cells. Higher ratios were associated with increases in reporter gene expression (Table II). Similar results were obtained with Ad.CMV-βgal (Table II). Studies performed with Ad.DF3-βgal demonstrated a lower background with uncontaminated PB mononuclear cells and enhanced sensitivity with detection of one MCF-7 cell/5 x 10^5 PB cells (Table II). Similar results were obtained with Ad.DF3-βgal when ZR-75-1 breast cancer cells were mixed with PB cells (data not shown). Other studies

were performed on BM cells that had been contaminated (0.1%) with DF3/MUC1-positive breast, lung, prostate, and ovarian cancer cells. The contaminated BM cells demonstrated a dramatic elevation in reporter activity when using Ad.DF3-βgal (Fig. 3A). Furthermore, contamination of BM with increasing numbers of MCF-7 cells resulted in higher levels of Ad.DF3-βgal-mediated reporter gene expression, while there was no increase in β-galactosidase expression when the BM cells were contaminated with DF3/MUC1 negative T98G glioblastoma cells (Fig. 3B).

To extend the observation of selective adenoviral-mediated reporter gene expression, we explored other approaches for detection of contaminating carcinoma cells. BM mononuclear cells with and without contaminating MCF-7 cells were infected with Ad.DF3-βgal and then visualized for X-gal staining. Using this approach, the MCF-7 cells could be readily identified by blue staining (Fig. 4A and B). The contaminating cells were also readily apparent by fluorescence microscopy after staining with the fluorescence substrate FDG (Figs. 4C and D). Cells that expressed β-galactosidase also reacted with MAb DF3 (data not shown), a monoclonal antibody that detects DF3/MUC1[21]. These findings indicated that histochemical, as well as biochemical, approaches can be used for detection of contaminating tumor cells by adenoviral-mediated reporter gene expression.

The selectivity of adenoviral-mediated gene transduction for contaminating tumor cells supported the possibility of using this approach to purge hematopoietic cell populations. Previous studies have documented the strategy of expressing the HSV-tk gene

for selective killing by GCV[20]. To exploit this strategy for purging, adenovirus carrying HSV-tk under control of the CMV or DF3/MUC1 promoters was used to transduce PB cells pre-mixed with tumor cells. As determined by clonogenic survival, infection at a MOI of 10 followed by GCV treatment (10 to 1000 μM) resulted in the elimination of over 6-logs of contaminating MCF-7 cells. Infection with Ad.DF3-tk at a MOI of 100 and then treatment with 100 μM GCV killed approximately 6-logs of cancer cells (Fig. 5A). In addition, this approach effectively eliminated other contaminating breast, prostate, lung and glioblastoma tumor cells pre-mixed with BM cells (Fig. 5B).

A potential adverse effect of ex vivo purging is toxicity to hematopoietic progenitor cells. We thus assessed the effects of adenoviral infection and GCV treatment on CFU-GM and BFU-E. Infection with Ad.CMV-tk or Ad.DF3-tk at a MOI of 10 followed by GCV (100 μM) treatment had little effect on CFU-GM and BFU-E as compared to GCV alone (≤10% cytotoxicity). Adenovirus infection alone at a MOI of 10 had little if any effect on colony formation (Table III). At a MOI of 100, there was a 17-19% decrease in BFU-E and CFU-GM when Ad.CMV-tk and GCV were used, while there was less of an effect with Ad.DF3-tk and GCV (Table III). Limiting dilution assays were also performed on enriched $CD34^+$ cells to assess the effects of adenovirus and GCV treatment on long-term culture initiating cells (LTC-ICs). The results demonstrate that infection with Ad.CMV-tk with or without GCV treatment has little if any effect on the regeneration and differentiation of the primitive progenitor cells (Fig. 6). Additional experiments were

performed to determine if adenovirus is detectable in the progeny cells after adenoviral purging of progenitor cells. CFU-GMs and BFU-Es were picked from methycellulose and cultured with 293 cells. No live adenovirus was rescued in three separate experiments. RT-PCR analysis of CFU-GM and BFU-E colonies failed to detect any transgene expression mediated by recombinant adenovirus (data not shown). Importantly, the finding that PCR analysis did not detect the presence of adenoviral E1a sequences indicated no wild type adenovirus replication.

DISCUSSION

A major issue for autologous BM or PB transplantation in breast cancer patients is the potential risk of collecting and reinfusing tumor cells. In this context, a study using histochemical detection has demonstrated BM involvement in 50% of patients with localized breast cancers and both BM (70%) and PB (22.5%) involvement in patients with Stage IV disease[5]. Gene transfer may provide one strategy for improving the detection and purging of tumor cells in BM or PB preparations. However, the presently available gene delivery systems generally lack target cell specificity. Ligand-DNA complexes, DNA-liposome complexes and direct transfer of DNA are limited by a low efficiency of gene transduction[37-40] . Moreover, the use of retroviral vectors for detection or purging of cancer cells in hematopoietic stem cell preparations could be limited by dependence on replication of the target cell. By contrast, replication-defective adenoviral vectors represent a highly efficient approach for in vitro gene transfer. One potential limitation of this vector system could be transduction of reporter or therapeutic genes into hematopoietic as well as tumor cells. However, the present studies demonstrate that adenovirus is markedly inefficient in the transduction of BM and PB, as compared to carcinoma, cells. Importantly, transduction of purified $CD34^+$ hematopoietic stem and progenitor cells is also inefficient compared to that of cancer cells. Another study has recently reported similar results in BM and CD34+ cell preparations[41]. Our results further indicate that the $CD34^+$ cell populations express low to undetectable levels of the

αvβ3 and αvβ5 integrins. Internalization of adenovirus requires interaction of the adenoviral penton base with αv integrins[35,36]. Consequently, the absence of detectable αv integrin subunits on $CD34^+$ cells and their high level expression on diverse cancer cells provides a mechanistic explanation for the selectivity of transduction.

The finding that adenoviral-mediated gene transduction is inefficient in BM and PB cell preparations compared to carcinoma cells supported the potential for using this approach to detect contaminating tumor cells. Transduction of the luciferase or β-galactosidase genes demonstrated a correlation between reporter expression and the number of contaminating cells. Expression of the reporter resulted in the detection of one cancer cell in 5 x 10^5 BM or PB cells. By contrast, an immunohistochemical method using antibodies against cytokeratin detects one tumor cell in 4 x 10^5 BM cells[5]. Moreover, we found that Ad.DF3-βgal transduction can be adapted for histochemical detection and thereby morphological examination by staining with X-gal or FDG. Furthermore, the use of the tumor-selective promoter resulted in lower backgrounds with uncontaminated hematopoietic cell preparations. We previously demonstrated that use of the DF3 promoter in adenoviral vectors provides an efficient and selective approach to target expression of heterologous genes in breast cancer cells[20]. There are presently several other tumor-specific or -selective promoter sequences that have been used to confer selective expression of heterologous genes in tumor cells[42-45]. The present results suggest that use of a tumor-selective promoter

in the context of an adenoviral vector can provide a highly sensitive approach for the detection of cancer cells in hematopoietic cell preparations. Studies will now be needed that directly compare the sensitivity of the present approach with other techniques used for detection of contaminating carcinoma cells.

The differential sensitivity of hematopoietic as compared to carcinoma cell transduction by adenoviral vectors further supported the use of this approach to purge contaminating tumor cells. Previous studies have demonstrated that purging BM preparations with 4-hydroperoxycyclophosphamide (4-HC) can lead to 2-3 logs of tumor cell depletion[12,17]. The use of immunomagnetic separation in combination with 4-HC eliminated up to 5 logs of tumor cells[12]. However, this approach significantly reduced the recovery of CFU-GM[12]. Monoclonal antibodies (MAbs) linked with toxin proteins have also been used for in vitro purging of bone marrow. MAb DF3 linked to ricin resulted in the elimination of 2-3 logs of breast tumor cells[13]. However, this approach also resulted in the reduction of CFU-GM formation. The present studies demonstrate that adenoviral mediated gene transduction using Ad.DF3-tk and GCV treatment results in the elimination of 6 logs of contaminating breast cancer cells. Importantly, there was little effect of Ad.DF3-tk transduction and GCV treatment on recovery of CFU-GM and BFU-E. Moreover, the adenovirus mediated transduction of tk to confer GCV sensitivity had little effect on LTC-ICs of enriched $CD34^+$ cells. Since completion of the present studies, another report has demonstrated that adenoviral vectors

expressing wild type p53 can be used to purge breast cancer cells mixed with normal bone marrow[41]. Other studies have demonstrated that adenoviruses can be used to selectively transduce cancer cells with genes that induce apoptosis[46] and to increase transduction of plasmid vectors coding for toxin genes[41]. Thus, combining several adenoviral-mediated strategies could be useful in increasing the efficacy of purging contaminating cancer cells in hematopoietic cell preparations.

Finally, the present results suggest that adenoviral-mediated gene transduction could be useful for the detection and elimination of diverse carcinomas contaminating bone marrow and peripheral blood collections. In addition to studies with breast cancer cells, adenoviral-mediated transduction was highly efficient for cells derived from lung, prostate and ovarian carcinomas. As the DF3/MUC1 antigen is overexpressed in breast, lung, prostate and ovarian cancers[21-23], adenoviral vectors containing the DF3/MUC1 promoter could be used in these settings to further increase selectivity of gene transduction. Alternatively, other tumor-selective DNA regulatory elements can be used in a similar context. The present results support the use of replication defective adenoviral vectors with the DF3/MUC1 promoter for purging hematopoietic cell preparations in the clinical setting.

CONCLUSIONS

Our studies demonstrate that replication defective adenoviral vectors containing the DF3/MUC1 carcinoma-selective promoter can be used to selectively transduce contaminating carcinoma cells in PB and BM. The sensitivity of this approach will need to be compared directly with that of other techniques currently being used in clinical setting. However, our findings suggest that the use of adenoviral vectors for detection and purging of contaminating breast cancer cells may be superior to those currently avaiable. Future investigations are being directed toward the development of this approach for clinical studies.

REFERENCES

1. Peters, W. P., E. J. Shpall, R. B. Jones, G. A. Olsen, R. C. Bast, J. P. Gockerman, and J. O. Moore. 1988. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. *J. Clin. Oncol.* 6:1368-1376.

2. Kennedy, M. J., R. A. Beveridge, S. D. Rowley, G. B. Gordon, M. D. Abeloff, and N. E. Davidson. 1991. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. *J. Natl. Cancer Inst.* 83:920-926.

3. Antman, K., L. Ayash, A. Elias, C. Wheeler, M. Hunt, J. P. Eder, B. A. Teicher, J. Critchlow, J. Bibbo, L. E. Schnipper, et al. 1992. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. *J. Clin. Oncol.* 10:102-110.

4. Peters, W. P., M. Ross, J. J. Vredenburgh, B. Meisenberg, L. B. Marks, E. Winer, J. Kurtzberg, R. C. Bast Jr., R. Jones, E. Shpall, et al. 1993. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. *J. Clin. Oncol.* 11:1132-1143.

5. Ross, A. A., B. W. Cooper, H. M. Lazarus, W. Mackay, T. J. Moss, N. Ciobanu, M. S. Tallman, M. J. Kennedy, N. E. Davidson, D. Sweet, et al. 1993. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer

patients using immunocytochemical and clonogenic assay techniques. *Blood.* 82:2605-1210.

6. Cote, R. J., P. P. Rosen, M. L. Lesser, L. J. Old, and M. P. Osborne. 1991. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. *J. Clin. Oncol.* 9:1749-1756.

7. Diel, I. J., M. Kaufmann, R. Goerner, S. D. Costa, S. Kaul, and G. Bastert. 1992. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. *J. Clin. Oncol.* 10:1234-1539.

8. Molino, A., M. Colombatti, F. Bonetti, M. Zardini, F. Pasini, A. Perini, G. Pelosi, G. Tridente, D. Veneri, and G. L. Cetto. 1991. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. *Cancer.* 67:1033-1036.

9. Simpson, S. J., M. Vachula, M. J. Kennedy, H. Kaizer, J. S. Coon, R. Ghalie, S. Williams, and D. Van Epps. 1995. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. *Exp. Hematol.* 23:1062-1068.

10. Datta, Y. H., P. T. Adams, W. R. Drobyski, S. P. Ethier, V. H. Terry, and M. S. Roth. 1994. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. *J. Clin. Oncol.* 12:475-482.

11. Gerhard, M., H. Juhl, H. Kalthoff, H. W. Schreiber, C. Wagener, and M. Neumaier. 1994. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone

marrow aspirates by polymerase chain reaction. *J. Clin. Oncol.* 12:725-729.

12. Anderson, I. C., E. J. Shpall, D. S. Leslie, K. Nustad, J. Ugelstad, W. P. Peters, and R. C. Bast Jr. 1989. Elimination of malignant clonogenic breast cancer cells from human bone marrow. *Cancer Res.* 49:4659-4664.

13. Tondini, C., S. A. Pap, D. F. Hayes, A. D. Elias, and D. W. Kufe. 1990. Evaluation of monoclonal antibody DF3 conjugated wtih ricin as a specific immunotoxin for in vitro purging of human bone marrow. *Cancer Res.* 50:1170-1175.

14. Shpall, E. J., R. C. Bast Jr., W. T. Joines, R. B. Jones, I. Anderson, C. Johnston, S. Eggleston, M. Tepperberg, S. Edwards, and W. P. Peters. 1991. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. *Bone Marrow Transplant.* 7:145-151.

15. Shpall, E. J., R. B. Jones, R. C. Bast Jr., G. L. Rosner, R. Vandermark, M. Ross, M. L. Affronti, C. Johnston, S. Eggleston, M. Tepperburg, et al. 1991. 4-hydroperoxycyclophos-phamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemnotherapy and autologous marrow support: a phase I trial. *J. Clin. Oncol.* 9:85-93.

16. Myklebust, A. T., A. Godal, S. Juell, A. Pharo, and O. Fodstad. 1994. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. *Cancer Res.* 54:209-214.

17. Passos-Coelho, J., A. A. Ross, J. M. Davis, A. M. Huelskamp, B. Clarke, S. J. Noga, N. E. Davidson, and M. J. Kennedy. 1994. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. *Cancer Res.* 54:2366-2371.

18. Graham, F. L., J. Smiley, W. C. Russel, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.* 36:59-72.

19. Manome, Y., M. Abe, M. F. Hagen, H. A. Fine, and D. W. Kufe. 1994. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. *Cancer Res.* 54:5408-5413.

20. Chen, L., D. Chen, Y. Manome, Y. Dong, H. A. Fine, and D. W. Kufe. 1995. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. *J. Clin. Invest.* 96:275-2782.

21. Kufe, D., G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler, and J. Schlom. 1984. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. *Hybridoma.* 3:223-232.

22. Friedman, E. L., D. G. Hayes, and D. W. Kufe. 1986. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. *Cancer Res.* 46:5189-5194.

23. Maimonis, P., D. Hayes, C. O'Hara, and D. Kufe. 1990. Detection and characterization of a high molecular weight lung carcinoma-associated antigen. *Cancer Res.* 50:6738-6743.

24. Sutherland, H. J., P. M. Lansdorp, D. H. Henkelman, A. C. Eaves, and C. J. Eaves. 1990. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. *Proc. Natl. Acad. Sci. U.S.A.* 87:3584-3588.

25. Pasqualini, R., J. Bodorova, S. Ye, and M. E. Hemler. 1993. A study of the structure, function and distribution of β_5 integrins using novel anti-β_5 monoclonal antibodies. *J. Cell Science*. 105:101-111.

26. Herz, J., and R. D. Gerard. 1993. Adenovirus-mediated transfer of low-density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. *Proc. Natl. Acad. Sci. U.S.A.* 90:2812-2816.

27. Abe, M., and D. Kufe. 1993. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. *Proc. Natl. Acad. Sci. U.S.A.* 90:282-286.

28. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors. *In* Methods in Molecular Biology: Gene transfer and expression protocols. E. J. Murray, editor. The Humana Press, Inc., Clifton, N.J.

29. Jain, V. K., and I. T. Magrath. 1991. A chemiluminescent assay for quantitation of beta-galactosidase in the femtogram

range: application to quantitation of beta-galactosidase in lacZ-transfected cells. *Anal. Biochem.* 199:119-124.

30. Nolan, G. P., S. Fiering, J. F. Nicolas, and L. A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ. *Proc. Natl. Acad. Sci. U.S.A.* 85:2603-2607.

31. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. *J. Immunol.* 126:1614-1619.

32. Nolta, J. A., E. M. Smogorzewska, and D. B. Kohn. 1995. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. *Blood.* 86:101-110.

33. Zhang, W. W., P. E. Koch, and J. A. Roth. 1995. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. *Biotechniques.* 18:444-447.

34. Steel, R. G. D., and J. H. Torrie. 1960. Principles and Procedures of Statistics with Special Reference to the Biological Sciences. McGraw-Hill Book Company, New York.

35. Mathias, P., T. Wickham, M. Moore, and G. Nemerow. 1994. Multiple adenovirus serotypes use alpha v integrins for infection. *J. Virol.* 68:6811-6814.

36. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell.* 73:309-319.

37. Wu, G. Y., and C. H. Wu. 1988. Receptor-mediated gene delivery and expression in vivo. *J. Biol. Chem.* 263:14621-14624.

38. Wu, G. Y., J. M. Wilson, F. Shalaby, M. Grossman, D. A. Shafritz, and C. H. Wu. 1991. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. *J. Biol. Chem.* 266:14338-14342.

39. Nabel, E. G., G. Plautz, and G. J. Nabel. 1990. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. *Science.* 249:1285-1288.

40. Nabel, E. G., D. Gordon, Z. Y. Yang, L. Xu, H. San, G. E. Plautz, B. Y. Wu, X. Gao, L. Huang, and G. J. Nabel. 1992. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. *Hum. Gene Ther.* 3:649-656.

41. Seth, P., U. Brinkmann, G. N. Schwartz, D. Katayose, R. Gress, I. Pastan, and K. Cowan. 1996. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. *Cancer Res.* 56:1346-1351.

42. Vile, R. G., and I. R. Hart. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. *Cancer Res.* 53:962-967.

43. Vile, R. G., and I. R. Hart. 1993. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following

direct intratumoral injection of DNA. *Cancer Res.* 53:3860-3864.

44. Huber, B. E., C. A. Richards, and T. A. Krenitsky. 1991. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. *Proc. Natl. Acad. Sci. U.S.A.* 88:8039-8043.

45. Harris, J. D., A. A. Gutierrez, H. C. Hurst, K. Sikora, and N. R. Lemoine. 1994. Gene therapy for cancer using tumor-specific prodrug activation. *Gene Therapy*. 1:170-175.

46. Clarke, M. F., I. J. Apel, M. A. Benedict, P. G. Eipers,V. Sumantran, M. Gonzalez-Garcia, M. Doedens, N. Fukunaga, B. Davidson, J. E. Dick, A. J. Minn, L. H. Boise, C. B. Thompson, M. Wicha, and G. Nunez. 1995. A recombinant bcl-x_s adenovirus electively induces apoptosis in cancer cells but not in normal bone marrow cells. *Proc. Natl. Acad. Sci. U.S.A.* 92:11024-11028.

APPENDIX

TABLE I

FACS ANALYSIS OF INTEGRIN αv SUBUNIT AND αvβ3, αvβ5 HETERODIMERS IN $CD34^+$ CELLS AND CARCINOMA CELLS

Cell	Type	av	avβ3	avβ5
$CD34^+$	hematopoietic progenitor cells	-	-	-
MCF-7	breast cancer	++++	-	+++
BT-20	breast cancer	++++	-	++++
ZR-75	breast cancer	++++	-	+++
SKBR3	breast cancer	++++	-	+++
A549	lung cancer	++++	+	+++
DU145	prostate cancer	++++	++	+++
T98G	brain glioblastoma	++++	++	+++

Cells were stained with MAbs for αv subunit, αvβ3 and αvβ5 heterodimers as described in Materials and Methods. Quantitation was determined as described[25] on the basis of fluorescence intensity. ++++, values above 60; +++, between 30 and 60; ++, between 10 and 30; +, values between 5 and 10; -, values under 5.

TABLE II

ADENOVIRUS MEDIATED REPORTER GENE EXRESSION IN BREAST CANCER CELLS PREMIXED WITH PB MONONUCLEAR CELLS

MCF-7 per 10^6 PB	RLU per 10^5 Cells (Mean ± SEM) Ad.CMV-Luc	Ad.CMV-βgal	Ad.DF3-βgal
0	$1.1\pm0.2 \times 10^4$ (1)	$2.1\pm0.7 \times 10^3$ (1)	$0.5\pm0.3 \times 10^2$ (1)
2	$2.4\pm1.7 \times 10^4$ (2.3)	$3.5\pm0.4 \times 10^3$ (1.6)	$2.0\pm0.8 \times 10^2$ (4.0)*
10	$1.0\pm0.4 \times 10^5$ (10)*	$9.9\pm5.7 \times 10^3$ (5)*	$1.4\pm0.4 \times 10^3$ (28)*
10^2	$8.7\pm6.1 \times 10^5$ (83)+	$4.9\pm3.4 \times 10^4$ (23)*	$4.4\pm0.8 \times 10^3$ (90)+
10^3	$6.4\pm1.9 \times 10^6$ (615)+	$1.4\pm0.5 \times 10^5$ (172)+	$1.2\pm0.9 \times 10^5$ (2359)+
10^4	$3.2\pm1.7 \times 10^7$ (5947)+	$5.0\pm4.0 \times 10^6$ (2354)+	$0.6\pm0.3 \times 10^6$ (11843)+

MCF-7 cells were premixed with PB cells at the indicated ratios. The cells were incubated with Ad.CMV-Luc, Ad.CMV-βgal and Ad.DF3-βgal at a MOI of 10 for 2 h at 37°C. At 48 h post-infection, cells were harvested, lysed, and assayed for reporter activities using a luminometer. The reporter activities are presented as relative luminescent units (RLU) per 100,000 cells (Mean ± SEM) obtained from four experiments. A background value of 200 RLU from the uninfected cells was subtracted. The fold-increase of reporter activity relative to tumor-free PB cells (MCF-7 = 0) is in parenthesis (*, $p \leq 0.05$; +, $p \leq 0.001$).

TABLE III

PROGENITOR CELL GROWTH OF $CD34^+$ CELLS
TREATED WITH ADENOVIRUS AND GCV

Treatment	BFU-E	CFU-GM
Untreated	100	100
+GCV	91 ± 2.8*	90 ± 2.5*
+Ad.DF3-tk (MOI=10)	102 ± 4.1	100 ± 3.2
+Ad.DF3-tk (MOI =10) + GCV	91 ± 3.9	91 ± 2.8*
+Ad.DF3-tk (MOI = 100) + GCV	90 ± 3.3*	90 ± 3.0*
+Ad.CMV-tk (MOI = 10)	100 ± 3.2	100 ± 3.1
+Ad.CMV-tk (MOI = 10) + GCV	90 ± 3.0*	89 ± 3.0*
+Ad.CMV-tk (MOI = 100) + GCV	83 ± 3.9$^+$	81 ± 4.0$^{+\S}$

Enriched $CD34^+$ cells were treated with the indicated adenovirus for 24 h at 37°C, washed and cultured for 24 h. GCV (100 μM) was then added for 24 h. The cells were washed and then cultured in methylcellulose for 2 weeks. The number of colonies in the treated groups is expressed as the percentage (mean ± SEM from 4 experiments) of that for untreated controls (21.8 ± 7.3 BFU-E and 26 ± 5.9 CFU-GM per 1000 $CD34^+$ cells). *$p \leq 0.05$, $^+p \leq 0.001$ vs untreated control, $^\S p \leq 0.05$ vs GCV alone.

Figure 1. Analysis of adenovirus mediated reporter gene expression in PB, BM and breast cancer cells. A) PB and BM mononuclear cells. B) MCF-7 breast cancer cells. Cells were infected with Ad.CMV-Luc, Ad.CMV-βgal, or Ad.DF3-βgal at the indicated MOIs for 2 h at 37°C, washed and cultured for 48 h. Cells were then lysed and assayed for luciferase or β-galactosidase activity. The results are presented as relative luminescent units (RLU) in the indicated number of cells (Mean ± SEM). Results were obtained from 4-9 experiments.



Figure 2. Analysis of adenovirus mediated gene transfer in $CD34^+$ and bone marrow stromal cells. A) Two-color FACS analysis to detect β-galactosidase activity in enriched $CD34^+$ cells infected with Ad.CMV-βgal or Ad.DF3-βgal. At 24 h post-infection, $CD34^+$ cells were stained with PE-conjugated anti-CD34 MAb. Cells expressing β-galatosidase were visualized by the fluorescence substrate, FDG. B) β-galactosidase activity in enriched CD34 cells and bone marrow stromal cells infected with Ad.CMV-βgal or Ad.DF3-βgal. Cells were infected at a MOI of 10 for 2 h at 37°C, washed and cultured for 48 h. β-galactosidase activity was measured by a luminescence assay. The results are presented as relative luminescent units (RLU) in the indicated number of cells (Mean ± SEM for 3 samples). C) Determination of adenoviral DNA in adenovirus-infected $CD34^+$ and MCF-7 cells. Cells were infected with adenovirus (MOI = 10) at 37°C for 2 h. Cells were incubated with trypsin/EDTA solution at 37°C for 5 min and washed three times with medium. DNA extracted from 10^4 (lanes 2,4) and 10^3 (lanes 3,5) fluorescence-sorted CD34+ cells or MCF-7 cells infected with adenovirus were used for PCR amplification (25 cycles) of a 0.86 Kb sequence in the adenoviral E2B gene. Adenoviral DNA equivalent to 10^3, 10^4, and 10^5 pfu was used as a reference control.



Figure 3. Adenovirus mediated reporter gene expression in BM contaminated with cancer cells. A) BM mononuclear cells were mixed with 0.1% MCF-7, ZR-75, BT-20 (breast cancer), A549 (lung cancer), DU145 (prostate cancer), and SKOV3 (ovarian cancer) cells. The cells were incubated with Ad.DF3-βgal at a MOI of 10 for 2 h at 37°C. After 24 h, cells were lysed and assayed for reporter gene expression by chemiluminescence assay. B) BM mononuclear cells premixed with various ratios of MCF-7 or T98G cells were incubated with either Ad.CMV-βgal or Ad.DF3-βgal at a MOI of 1 for 2 h at 37°C, washed, and cultured for 24 h. β-galactosidase expression was measured by chemiluminescence assay. Similar results were obtained in three separate experiments.

A.



B.



Figure 4. Detection of contaminating breast cancer cells in BM by Ad.DF3-βgal. Cells were incubated with Ad.DF3-βgal (MOI = 10) for 2 h at 37°C, washed, cultured for 24 h, fixed and then stained with X-gal. (A) BM mononuclear cells without MCF-7 cells. (B) BM mononuclear cells containing 0.1% MCF-7 cells. Magnification X400. Cells were also incubated with FDG and observed under a fluorescent microscope. (C) Bright field. (D) Dark field. Magnification X1000. Arrows indicate breast cancer cells.



Figure 5. Effects of Ad.CMV-tk and Ad.DF3-tk infection followed by GCV treatment on the survival of cancer cells premixed in PB or BM mononuclear cells. Cancer cells were premixed with 10-fold excess of irradiated PB or BM cells. The cells were then incubated with recombinant adenoviruses at 37°C for 2 h. At 24 h post-infection, cells were treated with GCV at the indicated concentrations for 24 h, and were then replated on 30-mm plates in duplicate at serial dilutions ranging from 500 to 10^6 cells per well. Two weeks later, the number of colonies (>50 cells) was assessed by crystal violet staining. A) Clonogenic assay for MCF-7 breast cancer cells premixed in PB and infected with Ad.CMV-tk or Ad.DF3-tk at the indicated MOIs followed by GCV treatment. The results are expressed as survival fraction, i.e. colony numbers in plates treated with adenovirus and/or GCV as a fraction of that for untreated controls (mean ± SEM for 2-4 experiments). B) Clonogenic assay for carcinoma cells premixed in BM treated with Ad.CMV-tk at a MOI of 10 and GCV.



Figure 6. Limiting dilution analysis of LTC-ICs for primitive progenitor cells. Enriched $CD34^+$ cells were treated as described in Table III, and seeded onto irradiated marrow feeders in 96-well plates at concentrations of 55 to 4000 cells/well and 20 wells per concentration. The number of clonogenic wells was assessed after 5 wks of suspension culture and 2 wks of growth in methylcellulose. The frequency of LTC-ICs was calculated by plotting the input cell number against the proportion of negative wells. The best linear fit and standard errors were determined from the data. A) Untreated control. B) Ad.CMV-tk infection (MOI = 10). C) Ad.CMV-tk (MOI = 10) and GCV (100 μM) treatment. Similar results were obtained in two independent experiments.



Received 2/8/00

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y) 26 Jan 00

MEMORANDUM FOR Administrator, Defense Technical Information Center, ATTN: DTIC-OCA, 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for the following Awards.

DAMD17-86-C-6169	ADB116203
DAMD17-94-J-4056	ADB218947
DAMD17-94-J-4394	ADB220575
DAMD17-94-J-4358	ADB236080
DAMD17-94-J-4169	ADB236753
DAMD17-94-J-4049	ADB234453
DAMD17-94-J-4080	ADB218909
DAMD17-94-J-4080	ADB233428
DAMD17-94-J-4431	ADB220348
DAMD17-94-J-4335	ADB234557
DAMD17-94-J-4388	ADB218872
DAMD17-94-C-4081	ADB246577
DAMD17-94-J-4025	ADB238010
DAMD17-94-J-4080	ADB241898
MIPR 96MM6720	ADB240182
MIPR 96MM6720	ADB226818

Request the limited distribution statement for Accession Document Numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Virginia Miller at DSN 343-7327 or by email at virginia.miller@det.amedd.army.mil.

FOR THE COMMANDER:

PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management